– SWITZERLAND, Schlieren – Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the successful completion of a CHF 7.5 million Series B equity financing round.
The company also announced the appointment of Dr Axel Polack and CEO, Anna Sumeray to the Board of Directors.
The new funds will be added to the previous seed and Series A financings of CHF 10.3 million, bringing the total capital raised to date by Virometix to CHF 17.8 million.
This round included participation from existing and new private investors and will ensure the company can complete the phase 1 clinical trial of its lead asset V-306 in RSV (respiratory syncytial virus), advance preclinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.
CEO, Anna Sumeray said: “We are delighted with the continued support and confidence from our existing investors and very happy to have attracted interest from new investors. We are excited about the differentiation of our platform and look forward to generating positive data over the coming months.”
About Dr Axel Polack
Dr Polack holds a Medical Doctorate degree from the Albert-Ludwigs-Universität Freiburg and Habilitation (postdoctoral lecture qualification) in Virology from the Ludwig-Maximilians-Universität Munich. He has experience as a board member and a biotech investor and was a partner at TVM Capital from 2000– 2014.
About Anna Sumeray
Anna Sumeray is the CEO of Virometix and has more than has over 25 years of experience in the life sciences sector with a combination of strategic consultancy, hands-on P&L leadership and deal transaction experience in big pharmaceutical and small biotechnology companies, globally, across Europe and within individual countries.
About Virometix
Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix’ proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability.
For more information: https://www.virometix.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
